Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Preliminary Amendment
The preliminary amendment dated 12/43/2022 has been entered. Claims 1-21 are pending and under examination.
Priority
Applicant’s claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, 365(c), or 386(c) is acknowledged. The earliest possible effective filing date for the instant claims is December 16, 2021 based on the filing date of the provisional application 63/290,164
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 3-6, 8, 14 and 16-17 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claims 3-6, 8, 14 and 16-17 all recite the limitation "….vaccines comprising the GAd20 virus, …. comprising the MVA virus, or ….. comprising the GAd20 virus and …. vaccines comprising the MVA virus..”. It is unclear if this recited vaccine GAd20 virus comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 1. It is unclear if this recited vaccine MVA virus comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 3. If the recited vaccine GAd20 virus does not comprise a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 1 and if the recited vaccine MVA virus does not comprise a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:3, there is insufficient antecedent basis for the GAd20 virus and the MVA virus recitation. For the purpose of compact prosecution, it has been interpreted that the recited “vaccine GAd20 virus” means the “vaccine GAd20 virus comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 1” and that the recited “vaccine MVA virus” means the “vaccine MVA virus comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 3”.
Appropriate correction is required for all the claims reciting the vaccines only as GAd20 virus or MVA virus .
Claims 15, 20 and 21 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claims 15, 20 and 21 all recite “…a vaccine comprising the GAd20….., a vaccine comprising the MVA virus…..”. It is unclear if this recited vaccine GAd20 virus comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 1. It is unclear if this recited vaccine MVA virus comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 3. If the recited vaccine GAd20 virus does not comprise a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 1 and if the recited vaccine MVA virus does not comprise a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:3, there is insufficient antecedent basis for the GAd20 virus and the MVA virus recitation. For the purpose of compact prosecution, it has been interpreted that the recited “vaccine GAd20 virus” means the “vaccine GAd20 virus comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 1” and that the recited “vaccine MVA virus” means the “vaccine MVA virus comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 3”.
Appropriate correction is required.
Claims 6 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 6 recites the limitation "….the anti-CTLA-4 antibody….”. Claim 8 recites the limitation " ….the anti-PD-1 antibody …”. There is insufficient antecedent basis for the “the antibody” limitations in claims 6 and 8. Both claims depend on claim 1 and there is no mention of any antibody in claim 1.
Appropriate correction is required.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(d):
(d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph:
Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
Claim 10 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 10 is dependent on claim 1. Claim 1 is drawn to a method of treating or preventing prostate cancer, comprising administering a treatment regimen comprising: two or more vaccines comprising a GAd20 virus that, in turn, comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 1 ….” Claim 10 fails to further limit the subject matter of the claim upon which it depend. Instead, the claim recitation “….wherein each of the: one or more GAd20 virus, …...” is broader in scope. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements.
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 1-21 are rejected under 35 U.S.C. § 112 (a), or 35 U.S.C. § 112 (pre-AIA ) first paragraph, because the specification, while being enabling for a method of treating prostate cancer, it does not reasonably provide enablement for a method of preventing prostate cancer. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.
The instant specification fails to provide information that would allow the skilled artisan to fully practice the instant invention without undue experimentation. Attention is directed to In re Wands, 8 USPQ2d 1400 (CAFC 1988) at 1404 where the court set forth the eight factors to consider when assessing if a disclosure would have required undue experimentation. Citing Ex parte Forman, 230 USPQ 546 (BdApls 1986) at 547 the court recited eight factors: (1) the nature of the invention; (2) the state of the prior art; (3) the relative skill of those in the art; (4) the predictability or unpredictability of the art; (5) the breadth of the claims; (6) the amount of direction or guidance presented; (7) the presence or absence of working examples; and (8) the quantity of experimentation necessary. All of the Wands factors have been considered with regard to the instant claims, with the most relevant factors discussed below.
Nature of the invention: Claims 1-21 of the instant application are drawn to a method of treating or preventing prostate cancer in a subject, the method comprising administering to the subject a treatment regimen comprising: two or more vaccines comprising a GAd20 virus that comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 1 and one or more vaccines comprising a Modified Vaccinia Ankara (MVA) virus that comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 3 to thereby treat or prevent the prostate cancer. This method may further comprise administering a PD-1 antibody or a CTLA-4 antibody. Therefore, the invention encompasses preventing disorders such as any type of prostate cancer.
Breadth of the claims: The complex nature of the subject matter of this invention is greatly exacerbated by the breadth of the claims. The rejected claims are extremely broad. Applicant claims that the claimed vaccines (and antibodies) can be used prevent prostate cancer. Thus, the cited claims are deemed very broad since these claims read on essentially preventing any type of prostate cancer in any subject comprising the administration of the claimed vaccines (and PD-1 or CTLA-4 antibodies) which includes subjects at risk of developing any type of prostate cancer.
State of the Prior Art: While the state of the art with regard to the treatment of cancer is relatively high, the state of the art with regard to the prevention of cancer is underdeveloped. This is because there would be no way to determine that cancer would have predictably occurred without treatment.
Regarding prevention of cancer, the American Cancer Society maintains that “There's no sure way to prevent cancer, but you can help reduce your risk by making healthy choices like eating right, staying active, and not smoking” (American Cancer Society. Cancer Risk and Prevention. https://www.cancer.org/cancer/risk-prevention.html).
Predictability/Unpredictability in the Art: It is noted that the vaccine art is unpredictable, requiring each embodiment to be individually assessed for physiological activity in preventing diseases. In re Fisher, 427 F.2d 833, 166 USPQ 18 (CCPA 1970) indicates that the more unpredictable an area is, the more specific enablement is necessary in order to satisfy the statute. In the instant case, the instant claimed invention is highly unpredictable since one skilled in the art would recognize that the recitation encompasses the prevention of prostate cancer and treating subjects that could be at risk of developing and those subjects suspected of having prostate cancer. Thus, the skilled artisan would view that the prevention of prostate cancer encompassed by the claims, (by administering to the subject a treatment regimen comprising: two or more vaccines comprising a GAd20 virus that comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 1 and one or more vaccines comprising a Modified Vaccinia Ankara (MVA) virus that comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 3. And this administration may further comprise administering a PD-1 antibody or a CTLA-4 antibody), is highly unpredictable.
Guidance of the Specification/Working Examples: Applicant has only provided working examples suggesting that the vaccines and antibodies may treat prostate cancer cells. Thus, the specification fails to provide sufficient evidence in support of prevention of those suspected of having or at risk of developing any type of prostate cancer and recited in the instant claims.
Additionally, the examples provided do not demonstrate the prevention of any type of prostate cancer. Additionally, the disclosure does not discuss, or demonstrate through working examples, a method that could be used to determine that recurrence of diseases/disorders was prevented using the claimed agents as there is no disclosed method to determine that recurrence of prostate cancer would have predictably occurred without treatment.
The Quantitation of Experimentation Required: In order to practice Applicants invention, it would be necessary for one to design and conduct an exhaustive amount of complex experiments to demonstrate that the claimed compounds could be administered to a subject at risk of developing prostate cancer. The population of subjects could include any subject, and thus the quantitation of experimentation is unreasonably large. Therefore, in order to practice the claimed invention, the amount of experimentation required would be considered undue and burdensome.
In conclusion, Genentech, 108 F.3d at 1366, states that “a patent is not a hunting license. It is not a reward for search, but compensation for its successful conclusion” and “[p]atent protection is granted in return for an enabling disclosure of an invention, not for vague intimations of general ideas that may or may not be workable”. The prevention of prostate cancer is not enabled by the instant specification.
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary.
Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claims 1-21 are rejected under 35 U.S.C. 103 as being unpatentable over Bachman (US20230024133A1 published July 16, 2020; issued patent No. US 11,793,843 B2) in view of Tang (Drug Discovery Today d Volume 26, Number 8 d August 2021)
Bachman teaches methods of treating and preventing prostate cancer in a subject ({4553], claims, 51, 70 and 71) comprising administering a) a first vaccine derived from GAd20 comprising a polynucleotide encoding a polypeptide of SEQ ID NOs: 541, and b) a second vaccine derived from MVA comprising a polynucleotide encoding a polypeptide of SEQ ID NOs: 543 (Bachman’s claim 51, 70 and 71) as required by instant claims 1, 3, 15 and 20-21. SEQ ID NO: 541 is 100% identical to SEQ ID NO: 1 and SEQ ID NO: 543 is 100% identical to SEQ ID NO: 3. Please see below for sequence alignments between the instant application and Bachman.
SEQ ID NO: 1 AND 541
Title: US-18-080-634-1
Sequence: 1 QNLQNGGGSRSSATLPGRRR..........QLTRIAPPRSHCCFWEVNAP 1479
RESULT 1
US-16-737-950-541
(NOTE: this sequence has 5 duplicates in the database searched)
Sequence 541, US/16737950
Publication No. US20200222478A1
GENERAL INFORMATION
APPLICANT: Janssen Biotech, Inc.
TITLE OF INVENTION: Prostate Neoantigens and their uses
FILE REFERENCE: JBI6160USNP1
CURRENT APPLICATION NUMBER: US/16/737,950
CURRENT FILING DATE: 2020-01-09
PRIOR APPLICATION NUMBER: 62/913,969
PRIOR FILING DATE: 2019-10-11
PRIOR APPLICATION NUMBER: 62/883,786
PRIOR FILING DATE: 2019-08-07
PRIOR APPLICATION NUMBER: 62/851,273
PRIOR FILING DATE: 2019-05-22
PRIOR APPLICATION NUMBER: 62/790,673
PRIOR FILING DATE: 2019-01-10
NUMBER OF SEQ ID NOS: 980
SEQ ID NO 541
LENGTH: 1479
TYPE: PRT
ORGANISM: Artificial sequence
FEATURE:
OTHER INFORMATION: Heterologous protein
Query Match 100.0%; Score 8084; Length 1479;
Best Local Similarity 100.0%;
Matches 1479; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 QNLQNGGGSRSSATLPGRRRRRWLRRRRQPISVAPAGPPRRPNQKPNPPGGARCVIMRPT
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 QNLQNGGGSRSSATLPGRRRRRWLRRRRQPISVAPAGPPRRPNQKPNPPGGARCVIMRPT
Qy 61 WPGTSAFTKRSFAVTERIIDYWAQKEKGSSSFLRPSCDYWAQKEKISIPRTHLCLVLGVL
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 WPGTSAFTKRSFAVTERIIDYWAQKEKGSSSFLRPSCDYWAQKEKISIPRTHLCLVLGVL
Qy 121 SGHSGSRLYEAGMTLGGKILFFLFLLLPLSPFSLIFTEISCCTLSSEENEYLPRPEWQLQ
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 121 SGHSGSRLYEAGMTLGGKILFFLFLLLPLSPFSLIFTEISCCTLSSEENEYLPRPEWQLQ
Qy 181 VPFRELKNVSVLEGLRQGRLGGPCSCHCPRPSQARLTPVDVAGPFLCLGDPGLFPPVKSS
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 181 VPFRELKNVSVLEGLRQGRLGGPCSCHCPRPSQARLTPVDVAGPFLCLGDPGLFPPVKSS
Qy 241 ITGGKSTCSAPGPQSLPSTPFSTYPQWVILITELGMECTLGQVGAPSPRREEDGWRGGHS
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 241 ITGGKSTCSAPGPQSLPSTPFSTYPQWVILITELGMECTLGQVGAPSPRREEDGWRGGHS
Qy 301 RFKADVPAPQGPCWGGQPGSAPSSAPPEQSLLDWKFEMSYTVGGPPPHVHARPRHWKTDR
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 301 RFKADVPAPQGPCWGGQPGSAPSSAPPEQSLLDWKFEMSYTVGGPPPHVHARPRHWKTDR
Qy 361 DGHSYTSKVNCLLLQDGFHGCVSITGAAGRRNLSIFLFLMLCKLEFHACKIQNKNCPDFK
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 361 DGHSYTSKVNCLLLQDGFHGCVSITGAAGRRNLSIFLFLMLCKLEFHACKIQNKNCPDFK
Qy 421 KFDGPCGERGGGRTARALWARGDSVLTPALDPQTPVRAPSLTRAAAAVHYKLIQQPISLF
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 421 KFDGPCGERGGGRTARALWARGDSVLTPALDPQTPVRAPSLTRAAAAVHYKLIQQPISLF
Qy 481 SITDRLHKTFSQLPSVHLCSITFQWGHPPIFCSTNDICVTANFCISVTFLKPCFLLHEAS
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 481 SITDRLHKTFSQLPSVHLCSITFQWGHPPIFCSTNDICVTANFCISVTFLKPCFLLHEAS
Qy 541 ASQCHLFLQPQVGTPPPHTASARAPSGPPHPHESCPAGRRPARAAQTCARRQHGLPGCEE
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 541 ASQCHLFLQPQVGTPPPHTASARAPSGPPHPHESCPAGRRPARAAQTCARRQHGLPGCEE
Qy 601 AGTARVPSLHLHLHQAALGAGRGRGWGEACAQVPPSRGVLRFLDLKVRYLHSQWQHYHRS
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 601 AGTARVPSLHLHLHQAALGAGRGRGWGEACAQVPPSRGVLRFLDLKVRYLHSQWQHYHRS
Qy 661 GEAAGTPLWRPTRNVPFRELKNQRTAQGAPGIHHAASPVAANLCDPARHAQHTRIPCGAG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 661 GEAAGTPLWRPTRNVPFRELKNQRTAQGAPGIHHAASPVAANLCDPARHAQHTRIPCGAG
Qy 721 QVRAGRGPEAGGGVLQPQRPAPEKPGCPCRRGQPRLHTVKMWRAVAMMVPDRQVHYDFGL
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 721 QVRAGRGPEAGGGVLQPQRPAPEKPGCPCRRGQPRLHTVKMWRAVAMMVPDRQVHYDFGL
Qy 781 GVPGDSTRRAVRRMNTFYEAGMTLGEKFRVGNCKHLKMTRPNSKMALNSEALSVVSECGA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 781 GVPGDSTRRAVRRMNTFYEAGMTLGEKFRVGNCKHLKMTRPNSKMALNSEALSVVSECGA
Qy 841 SACDVSLIAMDSAFVQGKDWGVKKFIRRDFYAYKDFLWCFPFSLVFLQEIQICCHVSCLC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 841 SACDVSLIAMDSAFVQGKDWGVKKFIRRDFYAYKDFLWCFPFSLVFLQEIQICCHVSCLC
Qy 901 CICCSTRICLGCLLELFLSRALRALHVLWNGFQLHCQTEYNQKLQVNQFSESKSLYHREK
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 901 CICCSTRICLGCLLELFLSRALRALHVLWNGFQLHCQTEYNQKLQVNQFSESKSLYHREK
Qy 961 QLIAMDSAICEERGAAGSLISCETMPAILKLQKNCLLSLRTALTHNQDFSIYRLCCKRGS
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 961 QLIAMDSAICEERGAAGSLISCETMPAILKLQKNCLLSLRTALTHNQDFSIYRLCCKRGS
Qy 1021 LCHASQARSPAFPKPVRPLPAPITRITPQLGGQSDSSQPLLTTGRPQGWQDQALRHTQQA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1021 LCHASQARSPAFPKPVRPLPAPITRITPQLGGQSDSSQPLLTTGRPQGWQDQALRHTQQA
Qy 1081 SPASCATITIPIHSAALGDHSGDPGPAWDTCPPLPLTTLIPRAPPPYGDSTARSWPSRCG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1081 SPASCATITIPIHSAALGDHSGDPGPAWDTCPPLPLTTLIPRAPPPYGDSTARSWPSRCG
Qy 1141 PLGGNTTLQQLGEASQAPSGSLIPLRLPLLWEVRGQPDSFAALHSSLNELGEIARELHQF
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1141 PLGGNTTLQQLGEASQAPSGSLIPLRLPLLWEVRGQPDSFAALHSSLNELGEIARELHQF
Qy 1201 AFDLLIKSHFVQGKDWGLKKFIRRDFWGMELAASRRFSWDHHSAGGPPRVPSVRSGAAQV
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1201 AFDLLIKSHFVQGKDWGLKKFIRRDFWGMELAASRRFSWDHHSAGGPPRVPSVRSGAAQV
Qy 1261 QPKDPLPLRTLAGCLARTAHLRPGAESLPQPQLHCTLWFQSSELSPTGAPWPSRRPTWRG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1261 QPKDPLPLRTLAGCLARTAHLRPGAESLPQPQLHCTLWFQSSELSPTGAPWPSRRPTWRG
Qy 1321 TTVSPRTATSSARTCCGTKWPSSQEAALGLGSGLLRFSCGTAAIRKMHFSLKEHPPPPCP
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1321 TTVSPRTATSSARTCCGTKWPSSQEAALGLGSGLLRFSCGTAAIRKMHFSLKEHPPPPCP
Qy 1381 PEAFQRAAGEGGPGRGGARRGARVLQSPFCRAGAGEWLGHQSLRHVVGYGHLDTSGSSSS
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1381 PEAFQRAAGEGGPGRGGARRGARVLQSPFCRAGAGEWLGHQSLRHVVGYGHLDTSGSSSS
Qy 1441 SSWPNSKMALNSLNSIDDAQLTRIAPPRSHCCFWEVNAP 1479
|||||||||||||||||||||||||||||||||||||||
Db 1441 SSWPNSKMALNSLNSIDDAQLTRIAPPRSHCCFWEVNAP 1479
SEQ ID NO: 3 AND 543
Title: US-18-080-634-3
Sequence: 1 QNLQNGGGSRSSATLPGRRR..........AALGLGSGLLRFSCGTAAIR 1479
RESULT 2
US-16-737-950-543
Sequence 543, US/16737950
Publication No. US20200222478A1
GENERAL INFORMATION
APPLICANT: Janssen Biotech, Inc.
TITLE OF INVENTION: Prostate Neoantigens and their uses
FILE REFERENCE: JBI6160USNP1
CURRENT APPLICATION NUMBER: US/16/737,950
CURRENT FILING DATE: 2020-01-09
PRIOR APPLICATION NUMBER: 62/913,969
PRIOR FILING DATE: 2019-10-11
PRIOR APPLICATION NUMBER: 62/883,786
PRIOR FILING DATE: 2019-08-07
PRIOR APPLICATION NUMBER: 62/851,273
PRIOR FILING DATE: 2019-05-22
PRIOR APPLICATION NUMBER: 62/790,673
PRIOR FILING DATE: 2019-01-10
NUMBER OF SEQ ID NOS: 980
SEQ ID NO 543
LENGTH: 1480
TYPE: PRT
ORGANISM: Artificial sequence
FEATURE:
OTHER INFORMATION: Heterologous protein
Query Match 100.0%; Score 8084; Length 1480;
Best Local Similarity 100.0%;
Matches 1479; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 QNLQNGGGSRSSATLPGRRRRRWLRRRRQPISVAPAGPPRRPNQKPNPPGGARCVIMRPT
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 QNLQNGGGSRSSATLPGRRRRRWLRRRRQPISVAPAGPPRRPNQKPNPPGGARCVIMRPT
Qy 61 WPGTSAFTGMECTLGQVGAPSPRREEDGWRGGHSRFKADVPAPQGPCWGGQPGSAPSSAP
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 WPGTSAFTGMECTLGQVGAPSPRREEDGWRGGHSRFKADVPAPQGPCWGGQPGSAPSSAP
Qy 121 PEQSLLDDYWAQKEKISIPRTHLCWKFEMSYTVGGPPPHVHARPRHWKTDRDYWAQKEKG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 121 PEQSLLDDYWAQKEKISIPRTHLCWKFEMSYTVGGPPPHVHARPRHWKTDRDYWAQKEKG
Qy 181 SSSFLRPSCVPFRELKNVSVLEGLRQGRLGGPCSCHCPRPSQARLTPVDVAGPFLCLGDP
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 181 SSSFLRPSCVPFRELKNVSVLEGLRQGRLGGPCSCHCPRPSQARLTPVDVAGPFLCLGDP
Qy 241 GLFPPVKSSITEISCCTLSSEENEYLPRPEWQLQYEAGMTLGGKILFFLFLLLPLSPFSL
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 241 GLFPPVKSSITEISCCTLSSEENEYLPRPEWQLQYEAGMTLGGKILFFLFLLLPLSPFSL
Qy 301 IFLVLGVLSGHSGSRLKRSFAVTERIITGGKSTCSAPGPQSLPSTPFSTYPQWVILITEL
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 301 IFLVLGVLSGHSGSRLKRSFAVTERIITGGKSTCSAPGPQSLPSTPFSTYPQWVILITEL
Qy 361 DGHSYTSKVNCLLLQDGFHGCVSITGAAGRRNLSIFLFLMLCKLEFHACQWQHYHRSGEA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 361 DGHSYTSKVNCLLLQDGFHGCVSITGAAGRRNLSIFLFLMLCKLEFHACQWQHYHRSGEA
Qy 421 AGTPLWRPTRNVAMMVPDRQVHYDFGLKIQNKNCPDVLRFLDLKVRYLHSVPFRELKNQR
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 421 AGTPLWRPTRNVAMMVPDRQVHYDFGLKIQNKNCPDVLRFLDLKVRYLHSVPFRELKNQR
Qy 481 TAQGAPGIHHAASPVAANLCDPARHAQHTRIPCGAGQVRAGRGPEAGGGVLQPQRPAPEK
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 481 TAQGAPGIHHAASPVAANLCDPARHAQHTRIPCGAGQVRAGRGPEAGGGVLQPQRPAPEK
Qy 541 PGCPCRRGQPRLHTVKMWRACHLFLQPQVGTPPPHTASARAPSGPPHPHESCPAGRRPAR
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 541 PGCPCRRGQPRLHTVKMWRACHLFLQPQVGTPPPHTASARAPSGPPHPHESCPAGRRPAR
Qy 601 AAQTCARRQHGLPGCEEAGTARVPSLHLHLHQAALGAGRGRGWGEACAQVPPSRGHYKLI
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 601 AAQTCARRQHGLPGCEEAGTARVPSLHLHLHQAALGAGRGRGWGEACAQVPPSRGHYKLI
Qy 661 QQPISLFSITDRLHKTFSQLPSVHLCSITFQWGHPPIFCSTNDICVTANFCISVTFLKPC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 661 QQPISLFSITDRLHKTFSQLPSVHLCSITFQWGHPPIFCSTNDICVTANFCISVTFLKPC
Qy 721 FLLHEASASQFKKFDGPCGERGGGRTARALWARGDSVLTPALDPQTPVRAPSLTRAAAAV
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 721 FLLHEASASQFKKFDGPCGERGGGRTARALWARGDSVLTPALDPQTPVRAPSLTRAAAAV
Qy 781 GVPGDSTRRAVRRMNTFCGASACDVSLIAMDSACEERGAAGSLISCESLYHREKQLIAMD
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 781 GVPGDSTRRAVRRMNTFCGASACDVSLIAMDSACEERGAAGSLISCESLYHREKQLIAMD
Qy 841 SAIFVQGKDWGVKKFIRRDFTMPAILKLQKNCLLSLNSKMALNSEALSVVSEYEAGMTLG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 841 SAIFVQGKDWGVKKFIRRDFTMPAILKLQKNCLLSLNSKMALNSEALSVVSEYEAGMTLG
Qy 901 EKFRVGNCKHLKMTRPTEYNQKLQVNQFSESKRTALTHNQDFSIYRLCCKRGSLCHASQA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 901 EKFRVGNCKHLKMTRPTEYNQKLQVNQFSESKRTALTHNQDFSIYRLCCKRGSLCHASQA
Qy 961 RSPAFPKPVRPLPAPITRITPQLGGQSDSSQPLLTTGRPQGWQDQALRHTQQASPASCAT
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 961 RSPAFPKPVRPLPAPITRITPQLGGQSDSSQPLLTTGRPQGWQDQALRHTQQASPASCAT
Qy 1021 ITIPIHSAALGDHSGDPGPAWDTCPPLPLTTLIPRAPPPYGDSTARSWPSRCGPLGYAYK
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1021 ITIPIHSAALGDHSGDPGPAWDTCPPLPLTTLIPRAPPPYGDSTARSWPSRCGPLGYAYK
Qy 1081 DFLWCFPFSLVFLQEIQICCHVSCLCCICCSTRICLGCLLELFLSRALRALHVLWNGFQL
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1081 DFLWCFPFSLVFLQEIQICCHVSCLCCICCSTRICLGCLLELFLSRALRALHVLWNGFQL
Qy 1141 HCQGNTTLQQLGEASQAPSGSLIPLRLPLLWEVRGNSKMALNSLNSIDDAQLTRIAPPRS
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1141 HCQGNTTLQQLGEASQAPSGSLIPLRLPLLWEVRGNSKMALNSLNSIDDAQLTRIAPPRS
Qy 1201 HCCFWEVNAPFVQGKDWGLKKFIRRDFEAFQRAAGEGGPGRGGARRGARVLQSPFCRAGA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1201 HCCFWEVNAPFVQGKDWGLKKFIRRDFEAFQRAAGEGGPGRGGARRGARVLQSPFCRAGA
Qy 1261 GEWLGHQSLRWGMELAASRRFSWDHHSAGGPPRVPSVRSGAAQVQPKDPLPLRTLAGCLA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1261 GEWLGHQSLRWGMELAASRRFSWDHHSAGGPPRVPSVRSGAAQVQPKDPLPLRTLAGCLA
Qy 1321 RTAHLRPGAESLPQPQLHCTIARELHQFAFDLLIKSHKMHFSLKEHPPPPCPPHVVGYGH
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1321 RTAHLRPGAESLPQPQLHCTIARELHQFAFDLLIKSHKMHFSLKEHPPPPCPPHVVGYGH
Qy 1381 LDTSGSSSSSSWPQPDSFAALHSSLNELGELWFQSSELSPTGAPWPSRRPTWRGTTVSPR
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1381 LDTSGSSSSSSWPQPDSFAALHSSLNELGELWFQSSELSPTGAPWPSRRPTWRGTTVSPR
Qy 1441 TATSSARTCCGTKWPSSQEAALGLGSGLLRFSCGTAAIR 1479
|||||||||||||||||||||||||||||||||||||||
Db 1441 TATSSARTCCGTKWPSSQEAALGLGSGLLRFSCGTAAIR 1479
Bachman also teaches that each vaccine can be administered one or more times to the subject (claims 76 and 77) which encompasses the required two or more times of instant claim 2. The GAd20 vaccine may be administered in an amount of about 1x109 to about 1x1012 viral particles (vp) to a human subject during one administration [46072] and this range is similar to the required range of GAd20 VP as required in instant claim 4 and includes the dose of 1x1011 of instant claims 15 and 20-21. The MVA vaccine comprises about 1xl07 to 1x109 TCID50 (50% Tissue Culture Infective Dose) or IFU [4603] similar to the required range for MVA IFU required by instant claim 5 and includes the dose of 1x108 of instant claims 15 and 20-21. Bachman also teaches the administration of an additional cancer therapeutic agent being a CTLA-4 antibody and a PD-1 axis inhibitor, PD-1 antagonist that can be an antibody (claims 35, 36 72, 74, 76 and [4743]) as required by instant claims 6, 8, 16-17 and 20-21.
Bachman also discloses the nucleotide sequences found in GAd20, SEQ ID NO: 542, which is 100% identical to the SEQ ID NO: 2 of instant claims 10 and 18 and the nucleotide sequence found in MVA, SEQ ID NO: 544 which is 100% identical to SEQ ID NO: 4 of instant claim 12 and 19 (see sequence alignments below). In addition, the polynucleotides can encode a T cell enhancer (TCE) and a histidine tag for the GAd20 vaccine ([4764] [4769]) (instant claim 11) and for the MVA vaccine ([4779] [4784]) (instant claim 13).
SEQ ID NO: 2 AND 542
Title: US-18-080-634-2
Sequence: 1 cagaacctgcagaacggcgg..........tttgggaagtgaacgcccca 4437
RESULT 1
US-16-737-950-542
(NOTE: this sequence has 5 duplicates in the database searched)
Sequence 542, US/16737950
Publication No. US20200222478A1
GENERAL INFORMATION
APPLICANT: Janssen Biotech, Inc.
APPLICANT: Bachman, Kurtis
APPLICANT: Bhargava, Vipul
APPLICANT: Davis, Darryl
APPLICANT: Krishna, Vinod
APPLICANT: Leoni, Guido
APPLICANT: Pocalyko, David
APPLICANT: Safabakhsh, Pegah
APPLICANT: Sepulveda, Manuel
APPLICANT: Siegel, Derick
TITLE OF INVENTION: Prostate Neoantigens and their uses
FILE REFERENCE: JBI6160USNP1
CURRENT APPLICATION NUMBER: US/16/737,950
CURRENT FILING DATE: 2020-01-09
PRIOR APPLICATION NUMBER: 62/913,969
PRIOR FILING DATE: 2019-10-11
PRIOR APPLICATION NUMBER: 62/883,786
PRIOR FILING DATE: 2019-08-07
PRIOR APPLICATION NUMBER: 62/851,273
PRIOR FILING DATE: 2019-05-22
PRIOR APPLICATION NUMBER: 62/790,673
PRIOR FILING DATE: 2019-01-10
NUMBER OF SEQ ID NOS: 980
SEQ ID NO 542
LENGTH: 4437
TYPE: DNA
ORGANISM: Artificial sequence
FEATURE:
OTHER INFORMATION: Heterologous polynucleotide
Query Match 100.0%; Score 4437; Length 4437;
Best Local Similarity 100.0%;
Matches 4437; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 CAGAACCTGCAGAACGGCGGAGGCTCTAGAAGCTCTGCTACACTTCCTGGCAGGCGGCGG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 CAGAACCTGCAGAACGGCGGAGGCTCTAGAAGCTCTGCTACACTTCCTGGCAGGCGGCGG
Qy 61 AGAAGATGGCTGAGAAGAAGGCGGCAGCCTATCTCTGTGGCTCCTGCTGGACCTCCTAGA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61 AGAAGATGGCTGAGAAGAAGGCGGCAGCCTATCTCTGTGGCTCCTGCTGGACCTCCTAGA
Qy 121 CGGCCCAACCAGAAGCCTAATCCTCCTGGCGGAGCCAGATGCGTGATCATGAGGCCTACA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 121 CGGCCCAACCAGAAGCCTAATCCTCCTGGCGGAGCCAGATGCGTGATCATGAGGCCTACA
Qy 181 TGGCCTGGCACCAGCGCCTTCACCAAGAGAAGCTTTGCCGTGACCGAGCGGATCATCGAC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 181 TGGCCTGGCACCAGCGCCTTCACCAAGAGAAGCTTTGCCGTGACCGAGCGGATCATCGAC
Qy 241 TATTGGGCTCAAAAAGAGAAGGGCAGCAGCAGCTTCCTGCGGCCTAGCTGTGATTATTGG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 241 TATTGGGCTCAAAAAGAGAAGGGCAGCAGCAGCTTCCTGCGGCCTAGCTGTGATTATTGG
Qy 301 GCCCAGAAAGAAAAGATCAGCATCCCCAGAACACACCTGTGCCTGGTGCTGGGAGTGCTG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 301 GCCCAGAAAGAAAAGATCAGCATCCCCAGAACACACCTGTGCCTGGTGCTGGGAGTGCTG
Qy 361 TCTGGACACTCTGGCAGCAGACTGTATGAGGCCGGCATGACACTCGGCGGCAAGATCCTG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 361 TCTGGACACTCTGGCAGCAGACTGTATGAGGCCGGCATGACACTCGGCGGCAAGATCCTG
Qy 421 TTCTTCCTGTTCCTGCTGCTCCCTCTGAGCCCCTTCAGCCTGATCTTCACCGAGATCAGC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 421 TTCTTCCTGTTCCTGCTGCTCCCTCTGAGCCCCTTCAGCCTGATCTTCACCGAGATCAGC
Qy 481 TGCTGCACCCTGAGCAGCGAGGAAAACGAGTACCTGCCTAGACCTGAGTGGCAGCTGCAG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 481 TGCTGCACCCTGAGCAGCGAGGAAAACGAGTACCTGCCTAGACCTGAGTGGCAGCTGCAG
Qy 541 GTCCCCTTCAGAGAGCTGAAGAACGTTTCCGTGCTGGAAGGCCTGAGACAGGGCAGACTT
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 541 GTCCCCTTCAGAGAGCTGAAGAACGTTTCCGTGCTGGAAGGCCTGAGACAGGGCAGACTT
Qy 601 GGCGGCCCTTGTAGCTGTCACTGCCCCAGACCTAGTCAGGCCAGACTGACACCTGTGGAT
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 601 GGCGGCCCTTGTAGCTGTCACTGCCCCAGACCTAGTCAGGCCAGACTGACACCTGTGGAT
Qy 661 GTGGCCGGACCTTTCCTGTGTCTGGGAGATCCTGGCCTGTTTCCACCTGTGAAGTCCAGC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 661 GTGGCCGGACCTTTCCTGTGTCTGGGAGATCCTGGCCTGTTTCCACCTGTGAAGTCCAGC
Qy 721 ATCACAGGCGGCAAGTCCACATGTTCTGCCCCTGGACCTCAGAGCCTGCCTAGCACACCC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 721 ATCACAGGCGGCAAGTCCACATGTTCTGCCCCTGGACCTCAGAGCCTGCCTAGCACACCC
Qy 781 TTCAGCACATACCCTCAGTGGGTCATCCTGATCACCGAACTCGGCATGGAATGCACCCTG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 781 TTCAGCACATACCCTCAGTGGGTCATCCTGATCACCGAACTCGGCATGGAATGCACCCTG
Qy 841 GGACAAGTGGGAGCCCCATCTCCTAGAAGAGAAGAGGATGGCTGGCGCGGAGGCCACTCT
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 841 GGACAAGTGGGAGCCCCATCTCCTAGAAGAGAAGAGGATGGCTGGCGCGGAGGCCACTCT
Qy 901 AGATTCAAAGCTGATGTGCCCGCTCCTCAGGGCCCTTGTTGGGGAGGACAACCTGGATCT
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 901 AGATTCAAAGCTGATGTGCCCGCTCCTCAGGGCCCTTGTTGGGGAGGACAACCTGGATCT
Qy 961 GCCCCATCTTCTGCCCCACCTGAACAGTCCCTGCTGGATTGGAAGTTCGAGATGAGCTAC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 961 GCCCCATCTTCTGCCCCACCTGAACAGTCCCTGCTGGATTGGAAGTTCGAGATGAGCTAC
Qy 1021 ACCGTCGGCGGACCTCCACCTCATGTTCATGCCAGACCTCGGCACTGGAAAACCGACAGA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1021 ACCGTCGGCGGACCTCCACCTCATGTTCATGCCAGACCTCGGCACTGGAAAACCGACAGA
Qy 1081 GATGGCCACAGCTACACCAGCAAAGTGAACTGCCTCCTGCTGCAGGATGGCTTCCACGGC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1081 GATGGCCACAGCTACACCAGCAAAGTGAACTGCCTCCTGCTGCAGGATGGCTTCCACGGC
Qy 1141 TGTGTGTCTATTACTGGCGCCGCTGGCAGACGGAACCTGAGCATCTTTCTGTTTCTGATG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1141 TGTGTGTCTATTACTGGCGCCGCTGGCAGACGGAACCTGAGCATCTTTCTGTTTCTGATG
Qy 1201 CTGTGCAAGCTCGAGTTCCACGCCTGCAAGATCCAGAACAAGAACTGCCCCGACTTCAAG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1201 CTGTGCAAGCTCGAGTTCCACGCCTGCAAGATCCAGAACAAGAACTGCCCCGACTTCAAG
Qy 1261 AAGTTCGACGGCCCTTGCGGAGAAAGAGGCGGAGGCAGAACAGCTAGAGCCCTTTGGGCT
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1261 AAGTTCGACGGCCCTTGCGGAGAAAGAGGCGGAGGCAGAACAGCTAGAGCCCTTTGGGCT
Qy 1321 AGAGGCGACAGCGTTCTGACACCAGCTCTGGACCCTCAGACACCTGTTAGGGCCCCTAGC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1321 AGAGGCGACAGCGTTCTGACACCAGCTCTGGACCCTCAGACACCTGTTAGGGCCCCTAGC
Qy 1381 CTGACAAGAGCTGCCGCCGCTGTGCACTACAAGCTGATCCAGCAGCCAATCAGCCTGTTC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1381 CTGACAAGAGCTGCCGCCGCTGTGCACTACAAGCTGATCCAGCAGCCAATCAGCCTGTTC
Qy 1441 AGCATCACCGACCGGCTGCACAAGACATTCAGCCAGCTGCCAAGCGTGCACCTGTGCTCC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1441 AGCATCACCGACCGGCTGCACAAGACATTCAGCCAGCTGCCAAGCGTGCACCTGTGCTCC
Qy 1501 ATCACCTTCCAGTGGGGACACCCTCCTATCTTTTGCTCCACCAACGACATCTGCGTGACC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1501 ATCACCTTCCAGTGGGGACACCCTCCTATCTTTTGCTCCACCAACGACATCTGCGTGACC
Qy 1561 GCCAACTTCTGTATCAGCGTGACCTTCCTGAAGCCTTGCTTTCTGCTGCACGAGGCCAGC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1561 GCCAACTTCTGTATCAGCGTGACCTTCCTGAAGCCTTGCTTTCTGCTGCACGAGGCCAGC
Qy 1621 GCCTCTCAGTGCCACTTGTTTCTGCAGCCCCAAGTGGGCACACCTCCTCCACATACAGCC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1621 GCCTCTCAGTGCCACTTGTTTCTGCAGCCCCAAGTGGGCACACCTCCTCCACATACAGCC
Qy 1681 TCTGCTAGAGCACCTAGCGGCCCTCCACATCCTCACGAATCTTGTCCTGCCGGAAGAAGG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1681 TCTGCTAGAGCACCTAGCGGCCCTCCACATCCTCACGAATCTTGTCCTGCCGGAAGAAGG
Qy 1741 CCTGCCAGAGCCGCTCAAACATGTGCCAGACGACAGCACGGACTGCCTGGATGTGAAGAG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1741 CCTGCCAGAGCCGCTCAAACATGTGCCAGACGACAGCACGGACTGCCTGGATGTGAAGAG
Qy 1801 GCTGGAACAGCCAGAGTGCCTAGCCTGCACCTCCATCTGCATCAGGCTGCTCTTGGAGCC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1801 GCTGGAACAGCCAGAGTGCCTAGCCTGCACCTCCATCTGCATCAGGCTGCTCTTGGAGCC
Qy 1861 GGAAGAGGTAGAGGATGGGGCGAAGCTTGTGCTCAGGTGCCACCTTCTAGAGGCGTGCTG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1861 GGAAGAGGTAGAGGATGGGGCGAAGCTTGTGCTCAGGTGCCACCTTCTAGAGGCGTGCTG
Qy 1921 AGATTCCTGGACCTGAAAGTGCGCTACCTGCACAGCCAGTGGCAGCACTATCACAGATCT
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1921 AGATTCCTGGACCTGAAAGTGCGCTACCTGCACAGCCAGTGGCAGCACTATCACAGATCT
Qy 1981 GGCGAAGCCGCCGGAACACCCCTTTGGAGGCCAACAAGAAACGTGCCCTTCCGGGAACTG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1981 GGCGAAGCCGCCGGAACACCCCTTTGGAGGCCAACAAGAAACGTGCCCTTCCGGGAACTG
Qy 2041 AAGAACCAGAGAACAGCTCAGGGCGCTCCTGGAATCCACCATGCTGCTTCTCCAGTGGCC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 2041 AAGAACCAGAGAACAGCTCAGGGCGCTCCTGGAATCCACCATGCTGCTTCTCCAGTGGCC
Qy 2101 GCCAACCTGTGTGATCCTGCCAGACATGCCCAGCACACCAGGATTCCTTGTGGCGCTGGA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 2101 GCCAACCTGTGTGATCCTGCCAGACATGCCCAGCACACCAGGATTCCTTGTGGCGCTGGA
Qy 2161 CAAGTGCGCGCTGGAAGAGGACCTGAAGCAGGCGGAGGTGTTCTGCAACCTCAAAGACCC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 2161 CAAGTGCGCGCTGGAAGAGGACCTGAAGCAGGCGGAGGTGTTCTGCAACCTCAAAGACCC
Qy 2221 GCTCCTGAGAAGCCTGGCTGCCCTTGCAGAAGAGGACAGCCTAGACTGCACACCGTGAAA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 2221 GCTCCTGAGAAGCCTGGCTGCCCTTGCAGAAGAGGACAGCCTAGACTGCACACCGTGAAA
Qy 2281 ATGTGGCGAGCCGTGGCCATGATGGTGCCCGATAGACAGGTCCACTACGACTTTGGACTG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 2281 ATGTGGCGAGCCGTGGCCATGATGGTGCCCGATAGACAGGTCCACTACGACTTTGGACTG
Qy 2341 GGCGTGCCAGGCGATAGCACTCGGAGAGCCGTCAGACGGATGAACACCTTTTACGAAGCC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 2341 GGCGTGCCAGGCGATAGCACTCGGAGAGCCGTCAGACGGATGAACACCTTTTACGAAGCC
Qy 2401 GGGATGACCCTGGGCGAGAAGTTCAGAGTGGGCAACTGCAAGCACCTGAAGATGACCCGG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 2401 GGGATGACCCTGGGCGAGAAGTTCAGAGTGGGCAACTGCAAGCACCTGAAGATGACCCGG
Qy 2461 CCTAACAGCAAGATGGCCCTGAATAGCGAGGCCCTGTCTGTGGTGTCTGAATGTGGCGCC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 2461 CCTAACAGCAAGATGGCCCTGAATAGCGAGGCCCTGTCTGTGGTGTCTGAATGTGGCGCC
Qy 2521 TCTGCCTGTGACGTGTCCCTGATCGCTATGGACTCCGCCTTTGTGCAGGGCAAAGACTGG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 2521 TCTGCCTGTGACGTGTCCCTGATCGCTATGGACTCCGCCTTTGTGCAGGGCAAAGACTGG
Qy 2581 GGCGTGAAGAAGTTCATCCGGCGGGACTTCTACGCCTACAAGGACTTCCTGTGGTGCTTC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 2581 GGCGTGAAGAAGTTCATCCGGCGGGACTTCTACGCCTACAAGGACTTCCTGTGGTGCTTC
Qy 2641 CCCTTCTCTCTGGTGTTCCTGCAAGAGATCCAGATCTGCTGTCATGTGTCCTGCCTGTGC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 2641 CCCTTCTCTCTGGTGTTCCTGCAAGAGATCCAGATCTGCTGTCATGTGTCCTGCCTGTGC
Qy 2701 TGCATCTGCTGTAGCACCAGAATCTGCCTGGGCTGTCTGCTGGAACTGTTCCTGAGCAGA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 2701 TGCATCTGCTGTAGCACCAGAATCTGCCTGGGCTGTCTGCTGGAACTGTTCCTGAGCAGA
Qy 2761 GCCCTGAGAGCACTGCACGTGCTGTGGAACGGATTCCAGCTGCACTGCCAGACCGAGTAC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 2761 GCCCTGAGAGCACTGCACGTGCTGTGGAACGGATTCCAGCTGCACTGCCAGACCGAGTAC
Qy 2821 AACCAGAAACTGCAAGTGAACCAGTTCAGCGAGAGCAAGAGCCTGTACCACCGGGAAAAG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 2821 AACCAGAAACTGCAAGTGAACCAGTTCAGCGAGAGCAAGAGCCTGTACCACCGGGAAAAG
Qy 2881 CAGCTCATTGCCATGGACAGCGCCATCTGCGAAGAGAGAGGCGCCGCAGGATCTCTGATC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 2881 CAGCTCATTGCCATGGACAGCGCCATCTGCGAAGAGAGAGGCGCCGCAGGATCTCTGATC
Qy 2941 TCCTGCGAAACAATGCCCGCCATCCTGAAGCTGCAGAAGAATTGCCTCCTAAGCCTGCGA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 2941 TCCTGCGAAACAATGCCCGCCATCCTGAAGCTGCAGAAGAATTGCCTCCTAAGCCTGCGA
Qy 3001 ACCGCTCTGACACACAACCAGGACTTCAGCATCTACAGACTGTGTTGCAAGCGGGGCTCC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 3001 ACCGCTCTGACACACAACCAGGACTTCAGCATCTACAGACTGTGTTGCAAGCGGGGCTCC
Qy 3061 CTGTGCCATGCAAGCCAAGCTAGAAGCCCCGCCTTTCCTAAACCTGTGCGACCTCTGCCA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 3061 CTGTGCCATGCAAGCCAAGCTAGAAGCCCCGCCTTTCCTAAACCTGTGCGACCTCTGCCA
Qy 3121 GCTCCAATCACCAGAATTACCCCTCAGCTCGGCGGCCAGAGCGATTCATCTCAACCTCTG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 3121 GCTCCAATCACCAGAATTACCCCTCAGCTCGGCGGCCAGAGCGATTCATCTCAACCTCTG
Qy 3181 CTGACCACCGGCAGACCTCAAGGCTGGCAAGACCAAGCTCTGAGACACACCCAGCAGGCT
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 3181 CTGACCACCGGCAGACCTCAAGGCTGGCAAGACCAAGCTCTGAGACACACCCAGCAGGCT
Qy 3241 AGCCCTGCCTCTTGTGCCACCATCACAATCCCCATCCACTCTGCCGCTCTGGGCGATCAT
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 3241 AGCCCTGCCTCTTGTGCCACCATCACAATCCCCATCCACTCTGCCGCTCTGGGCGATCAT
Qy 3301 TCTGGCGATCCTGGACCAGCCTGGGACACATGTCCTCCACTGCCACTCACAACACTGATC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 3301 TCTGGCGATCCTGGACCAGCCTGGGACACATGTCCTCCACTGCCACTCACAACACTGATC
Qy 3361 CCTAGGGCTCCTCCACCTTACGGCGATTCTACCGCTAGAAGCTGGCCCAGCAGATGTGGA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 3361 CCTAGGGCTCCTCCACCTTACGGCGATTCTACCGCTAGAAGCTGGCCCAGCAGATGTGGA
Qy 3421 CCACTCGGAGGCAACACAACCCTCCAGCAACTGGGAGAAGCCTCTCAGGCTCCTAGCGGC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 3421 CCACTCGGAGGCAACACAACCCTCCAGCAACTGGGAGAAGCCTCTCAGGCTCCTAGCGGC
Qy 3481 TCTCTGATCCCTCTCAGACTGCCTCTCCTGTGGGAAGTTCGGGGCCAGCCTGATTCTTTT
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 3481 TCTCTGATCCCTCTCAGACTGCCTCTCCTGTGGGAAGTTCGGGGCCAGCCTGATTCTTTT
Qy 3541 GCCGCACTGCACAGCTCCCTGAACGAGCTGGGAGAGATCGCTAGAGAGCTGCACCAGTTC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 3541 GCCGCACTGCACAGCTCCCTGAACGAGCTGGGAGAGATCGCTAGAGAGCTGCACCAGTTC
Qy 3601 GCCTTCGACCTGCTGATCAAGAGCCACTTCGTGCAAGGCAAGGATTGGGGCCTCAAAAAG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 3601 GCCTTCGACCTGCTGATCAAGAGCCACTTCGTGCAAGGCAAGGATTGGGGCCTCAAAAAG
Qy 3661 TTTATCCGCAGAGACTTCTGGGGCATGGAACTGGCCGCCAGCAGAAGATTCAGCTGGGAT
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 3661 TTTATCCGCAGAGACTTCTGGGGCATGGAACTGGCCGCCAGCAGAAGATTCAGCTGGGAT
Qy 3721 CATCATAGCGCAGGCGGCCCACCTAGAGTGCCATCTGTTAGAAGCGGAGCTGCCCAGGTG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 3721 CATCATAGCGCAGGCGGCCCACCTAGAGTGCCATCTGTTAGAAGCGGAGCTGCCCAGGTG
Qy 3781 CAGCCTAAAGATCCTCTGCCACTGAGAACACTGGCCGGCTGCCTTGCTAGAACAGCCCAT
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 3781 CAGCCTAAAGATCCTCTGCCACTGAGAACACTGGCCGGCTGCCTTGCTAGAACAGCCCAT
Qy 3841 CTTAGACCTGGCGCCGAGTCTCTGCCTCAGCCACAACTGCACTGTACCCTGTGGTTCCAG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 3841 CTTAGACCTGGCGCCGAGTCTCTGCCTCAGCCACAACTGCACTGTACCCTGTGGTTCCAG
Qy 3901 TCCAGCGAGCTGTCTCCTACTGGTGCCCCTTGGCCATCTAGACGCCCTACTTGGAGAGGC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 3901 TCCAGCGAGCTGTCTCCTACTGGTGCCCCTTGGCCATCTAGACGCCCTACTTGGAGAGGC
Qy 3961 ACCACCGTGTCACCAAGAACCGCCACAAGCAGCGCCAGAACCTGTTGTGGCACAAAGTGG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 3961 ACCACCGTGTCACCAAGAACCGCCACAAGCAGCGCCAGAACCTGTTGTGGCACAAAGTGG
Qy 4021 CCCTCCAGCCAAGAAGCCGCTCTCGGACTTGGAAGCGGACTGCTGAGGTTCTCTTGTGGA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 4021 CCCTCCAGCCAAGAAGCCGCTCTCGGACTTGGAAGCGGACTGCTGAGGTTCTCTTGTGGA
Qy 4081 ACCGCCGCCATTCGGAAGATGCACTTTAGCCTGAAAGAACACCCTCCACCACCTTGTCCT
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 4081 ACCGCCGCCATTCGGAAGATGCACTTTAGCCTGAAAGAACACCCTCCACCACCTTGTCCT
Qy 4141 CCAGAGGCTTTCCAAAGAGCTGCTGGCGAAGGCGGACCTGGTAGAGGTGGTGCTAGAAGA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 4141 CCAGAGGCTTTCCAAAGAGCTGCTGGCGAAGGCGGACCTGGTAGAGGTGGTGCTAGAAGA
Qy 4201 GGTGCTAGGGTGCTGCAGAGCCCATTCTGTAGAGCAGGCGCAGGCGAATGGCTGGGCCAT
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 4201 GGTGCTAGGGTGCTGCAGAGCCCATTCTGTAGAGCAGGCGCAGGCGAATGGCTGGGCCAT
Qy 4261 CAGAGTCTGAGACATGTCGTCGGCTACGGCCACCTGGATACAAGCGGAAGCAGCTCTAGC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 4261 CAGAGTCTGAGACATGTCGTCGGCTACGGCCACCTGGATACAAGCGGAAGCAGCTCTAGC
Qy 4321 TCCAGCTGGCCTAACTCAAAAATGGCTCTGAACAGCCTGAACTCCATCGACGACGCCCAG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 4321 TCCAGCTGGCCTAACTCAAAAATGGCTCTGAACAGCCTGAACTCCATCGACGACGCCCAG
Qy 4381 CTGACAAGAATCGCCCCTCCTAGATCTCACTGCTGCTTTTGGGAAGTGAACGCCC